Impact of urinary FSH price: a cost-effectiveness analysis of recombinant and urinary FSH in assisted reproduction techniques in the USA
- 1 January 2002
- journal article
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 5 (3) , 265-269
- https://doi.org/10.1016/s1472-6483(10)61830-5
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UKHuman Reproduction, 2001
- Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP)Human Reproduction, 2000
- A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F®) with highly purified urinary FSH (Metrodin® HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injectionHuman Reproduction, 2000
- Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproductionHuman Reproduction, 1999
- Pharmaco-economic aspects of in-vitro fertilization in ItalyHuman Reproduction, 1999
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998
- Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniquesHuman Reproduction, 1997
- Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropinsFertility and Sterility, 1997
- A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilizationHuman Reproduction, 1995
- Probabilistic Sensitivity Analysis Using Monte Carlo SimulationMedical Decision Making, 1985